Mechanisms of resistance to chemoterapeutic and antiangiogenic drugs as novel targets for pancreatic cancer therapy

Starting date: January 1, 2011
Duration (months): 60
Departments: Medicine
Managers or local contacts: Melisi Davide
Keyword: pancreatic cancer, treatment resistance, angiogenesis

Sponsors:

A.I.R.C. Associazione Italiana per la Ricerca sul Cancro: Funds: assigned and managed by the department

Project participants

Davide Melisi: Associate Professor

Giampaolo Tortora

Sections
Medical Oncology Section

Publications
Title	Authors	Year
NF-κB as a target for pancreatic cancer therapy.	Carbone, C.; Melisi, Davide	2012
Pancreatic Cancer: between bench and bedside.	Melisi, Davide; A., Budillon	2012
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.	Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, Davide	2011
Emerging pathways and future targets for the molecular therapy of pancreatic cancer.	Vaccaro, V; Melisi, Davide; Bria, Emilio; Cuppone, F; Ciuffreda, L; Pino, Ms; Gelibter, A; Tortora, Giampaolo; Cognetti, F; Milella, M.	2011
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.	Melisi, Davide; Xia, Q.; Paradiso, G.; Ling, J.; Moccia, T.; Carbone, C.; Budillon, A.; Abbruzzese, J. L.; Chiao, P. J.	2011